VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

EHA 2016 | Is it possible to reach an operational cure for CML?

Giuseppe Saglio, MD from University of Turin, Turin, Italy discusses the influence of tyrosine kinase inhibitor (TKI) therapy on the treatment of chronic myeloid leukemia (CML). Over the past few years it has been shown that patients can achieve a status called operational cure, where it is possible for them to stop therapy – however, the number of patients holding this status is low. Prof Saglio holds hope that in the future this number will rise and mentions the potential of using a stronger TK inhibitor to increase the number of patients holding an operational cure. Recorded at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter